Imbed Biosciences

Executive Summary

Imbed Biosciences is a privately held medical device company based in Madison, Wisconsin, focused on advanced wound care through its proprietary Synthetic Antimicrobial Matrix (SAM™) technology. The company's FDA-cleared products are fully synthetic antimicrobial matrices designed for a range of wound types including acute, surgical, traumatic, and burn wounds. With a foundation in innovation and a clear regulatory pathway, Imbed Biosciences aims to address the growing need for infection prevention and improved healing outcomes in wound care. The company's technology differentiates itself by providing a synthetic alternative to biologic matrices, potentially offering cost and scalability advantages. Despite being private with limited publicly disclosed funding or revenue, the company has established a presence in a large and expanding wound care market, driven by an aging population and increasing incidence of chronic wounds and surgical procedures.

Upcoming Catalysts (preview)

• Q2 2027Expansion of FDA-cleared indications for SAM technology to include chronic or diabetic wounds60% success
• Q4 2026Strategic partnership or distribution agreement with a major wound care company50% success
• Q3 2027Publication of pivotal clinical trial results demonstrating superiority over standard of care40% success